Last reviewed · How we verify

Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona — Portfolio Competitive Intelligence Brief

Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
azelastine hydrochloride 0.05% azelastine hydrochloride 0.05% marketed H1-receptor antagonist (second-generation antihistamine) H1 receptor Allergy/Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AAADRS Clinical Research Center · 1 shared drug class
  2. Brian J Lipworth · 1 shared drug class
  3. GlaxoSmithKline · 1 shared drug class
  4. Goldman, Butterwick, Fitzpatrick and Groff · 1 shared drug class
  5. HK inno.N Corporation · 1 shared drug class
  6. Organon and Co · 1 shared drug class
  7. UCB Pharma · 1 shared drug class
  8. University Hospital, Grenoble · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona:

Cite this brief

Drug Landscape (2026). Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-ospedaliera-oo-rr-s-giovanni-di-dio-e-ruggi-d-aragona. Accessed 2026-05-17.

Related